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Abstract
Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these
drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long
term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance.80 mL/min treated
with tenofovir for at least 6 months and with at least one assessment of tenofovir plasma trough concentrations were
considered. Tenofovir-associated adverse events were defined as the appearance of pathological proteinuria, worsening of
renal function or bone demineralization. By multivariate regression analysis, we found that serum creatinine (p = 0.003) and
body weight (p = 0.002) were the factors independently associated with plasma tenofovir concentrations. In particular,
women with body weight,50 kg had significantly higher plasma tenofovir concentrations than those weighting .50 Kg
(160693 vs.71652 ng/mL, p,0.001). High tenofovir plasma trough concentrations and the age of the patients were
independently associated with the development of drug-related kidney and bone toxicity. In this retrospective study we
have shown that HIV-infected women with low body weight are at risk to be exposed to high tenofovir plasma trough
concentrations, ultimately resulting in a significant hazard to develop long-term tenofovir complications.
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Introduction
Tenofovir disoproxil fumarate (TDF) is one of the nucleotide
reverse transcriptase inhibitors (NRTI) most widely used as fist-
line therapy for HIV-infected patients [1–4]. TDF is relatively
well tolerated in most patients; however episodes of tubular
dysfunction (including the development of Fanconi’s syndrome),
significant decline in glomerular filtration rate and acute kidney
injury have often been reported [5–7]. These TDF-related
kidney disease events may not be reversible [7]. Emerging
clinical observations have also revealed considerable relationship
between TDF use and loss of bone density in HIV-infected
individual [8–10]. Taken together, these findings raise serious
concerns on the safe use of TDF in clinical practice. The
possibility to monitor early exposure of patients to TDF and
eventually implement individualized drug dosages has been,
however, only poorly explored [11,12].
Recent investigations have shown that low body weight is an
independent risk factor for TDF-associated renal dysfunction in
HIV-infected Japanese patients [13,14]. The Authors hypothe-
sized that small body weight was associated with reduced plasma
TDF clearance and thus high plasma TDF concentrations, which
could result in renal tubular dysfunction. This hypothesis has
been indirectly supported by a retrospective investigation in
Caucasian HIV-infected individuals showing significant associa-
tion between development of kidney impairment and higher
TDF plasma trough concentrations [15]. According to the
manufacturer’s instruction, the recommended TDF dose is
300 mg to be administered once a day in patients with creatinine
clearance .50 mL/min and every 48 h in patients with
creatinine clearance ranging from 30 to 49 mL/min. No specific
indications are usually given in patients with low body weight.
These observations suggest that some patients treated with
conventional dose regimens may be exposed to high plasma TDF
concentrations with an increased risk to develop drug-related
adverse events. The identification of factors predisposing to
overexposure to TDF may therefore contribute to improve the
safety of this drug.
In the present study we: I) evaluated the distribution of TDF
plasma trough concentrations in HIV-infected patients treated
with TDF at 300 mg qd; II) identified factors associated with TDF
plasma concentrations; III) assessed whether high TDF plasma
concentrations are independently associated with the development
of drug-related toxicity.
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Materials and Methods
Study population
Male and female HIV-infected patients referred to the
Department of Infectious Diseases of the L. Sacco University
Hospital with basal creatinine clearance .80 mL/min before
starting treatment with TDF were enrolled in the present study.
Pediatric subjects, patients with severe hepatic impairment or with
history of kidney or bone diseases were excluded from the present
study. All patients started TDF treatment at 300 mg given orally
every 24 hours (q.d.).
Adherence of patients to therapy was verified through direct
questioning during every outpatient visits. Data on self-reported
adherence were matched with data from our Pharmacy Depart-
ment in order to verify that patients effectively picked up the
adequate amount of antiretrovirals to fully cover the time between
visits. Only patients with high adherence to antiretroviral
medications (above 95% of the doses) were considered.
The present study is based on a retrospective analysis of routine
TDF pharmacokinetic evaluations carried out as day-by-day
clinical practice for the optimization of drug dosing in HIV-
infected patients. Written informed consent to patient’s manage-
ment (that is consent for diagnostic evaluations, drug administra-
tion and all other medical procedures) was collected prior to his
admission to the Department of Infectious Disease of the L. Sacco
Hospital. Patients agreed for the use of their records for
anonymized future analysis. In compliance with privacy laws,
the patients’ identification code was encrypted before performing
the statistical analyses. Given the retrospective observational
nature of the present investigation, no formal approval from the
local ethics committee was required according to the legislation of
the national drug agency (Agenzia Italiana del Farmaco, available
at www.agenziafarmaco.gov.it).
Study design
In the present retrospective study we considered HIV-infected
patients treated with TDF for at least six months and with at least
one assessment of TDF plasma trough concentration performed
by our laboratory between January 2011 and December 2012 (the
measurement of TDF was not available in our hospital before
January 2011). Patients already on TDF-based therapy before
January 2011 were included in the analysis provided that they
fulfilled the inclusion/exclusion criteria.
If more than one TDF concentration was available for each
patient we considered only the first drug assessment in the
Table 1. Main demographic, haematological and biochemical parameters of HIV-positive patients given tenofovir as part of their
maintenance antiretroviral therapy (data were given as mean 6 standard deviation).
Parametes Patients (n =100) Women (n=40) Men (n =60)
Tenofovir therapy, days 10426925 14156986 8246770
Age, years 4569 4468 45611
Protease inhibitors, % 63 65 69
Non nucleoside reverse transcriptase inhibitors, % 19 20 18
Raltegravir,% 18 15 13
Weight, Kg 62.6614.0 53.3612.2 68.6611.7
Body mass index, Kg/m2 21.763.8 20.564.4 22.563.3
Creatinine, mg/dL 0.960.7 0.760.2 1.060.5
Creatinine clearance, mL/min 96.4636.6 91.1637.7 100.0635.9
AST, IU/L 55676 46661 61685
ALT, IU/L 666133 49677 786160
CD4, cells/mL 4836271 4886293 4746254
HIV-RNA, cp/mL 3673632873 51361833 5642641866
Pts with HIV-RNA .100 cp/mL,% 16 17 15
HCV coinfection, % 31 30 33
HBV coinfection, % 12 13 9
HCV+HBV coinfection, % 3 3 4
doi:10.1371/journal.pone.0080242.t001
Figure 1. Box-plot of Tenofovir (TDF) plasma trough concen-
trations measured in 100 HIV-infected patients.
doi:10.1371/journal.pone.0080242.g001
Body Weight, Female Gender and Tenofovir Exposure
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multivariate analysis correlating TDF exposure with drug-related
toxicity. Any relevant clinical information on the clinical status of
the patient was also recorded (monitoring all adverse events,
monitoring of hematological, biochemical and immune-virologic
parameters, measurement of vital signs and physical examina-
tions).
TDF related adverse events were defined as episodes of
pathological proteinuria, worsening of renal function (at least
30% reduction in the creatinine clearance versus baseline) or bone
toxicity (reduced bone mineral density assessed by DEXA in
absence of menopause). Creatinine clearance was estimated with
the formula of Cockroft-Gault, as follows: GFR = (140-age)6body
weight/serum creatinine672. In female patients, the formula was
multiplied by a constant of 0.85.
Pharmacokinetic evaluations
Blood samples drawn into EDTA-containing vacutainersH were
collected from all patients 24 hours after the last drug intake (a
time window of65 min was directly verified by the nurse staff and
considered as acceptable), immediately before the next TDF
administration and placed immediately on ice after drawing. All
samples were centrifuged at 3000 g (+4uC), and then plasma was
separated and stored at 220uC.
After purification of plasma samples through solid-phase
extraction, TDF concentrations were determined using a liquid
chromatography method coupled with a mass spectrometry [16]
developed and validated according to FDA guidelines [17].
Chromatographic separation was achieved with a gradient
(acetonitrile and water with formic acid 0.05%) on a reversed
phase analytical column (Atlantis 4.6 mm 6150 mm, Waters,
Milan Italy). Detection of TDF was achieved by electrospray
ionization mass spectrometry in the positive ion mode.
Statistical analyses
Results were given as the mean (6 standard deviation) or
median (plus interquartile range) according to distribution of the
data based on results of the Kolmogorov-Smirnov normality test.
Multivariate regression analyses were performed using TDF
plasma concentrations as the dependent variable, with clinical
characteristics as the independent one. Comparisons of demo-
graphic, hematological and biochemical parameters, as well as
immune-virologic status (CD4 cell count, HIV viral load and co-
infection with HCV or HBV) between patients experiencing or not
TDF-related side effects were carried out using the unpaired t-test
or the Mann-Whitney test according to the distribution of the
data. The independent association between plasma TDF concen-
trations and drug-related toxicity was assessed by means of
multivariate logistic regression analysis using the event (yes or no)
as dichotomic dependent variable (MEDCALC, Software). A p
value of less than 0.05 was considered as statistically significant.
Results
Patients’ characteristics
One-hundred HIV-infected adult patients were included in the
present study. Forty-six of them were co-infected with hepatitis C
and/or hepatitis B. Patients were at a mean (6 standard deviation)
of 1042 (6925) days of therapy with TDF/emtricitabine. As
shown in Table 1, 63% of them were given concomitantly a
boosted protease inhibitor (31 patients were on atazanavir, 14 on
lopinavir, 10 on darunavir and 8 fosamprenavir), while the
remaining were on efavirenz (15%), nevirapine (4%), or raltegravir
(18%).
Distribution of TDF plasma trough concentrations
Overall, a wide distribution in the measured TDF plasma
trough concentrations was observed, with values ranging from 20
to 452 ng/mL (Figure 1). This distribution was associated with an
inter-patient variability in the plasma TDF concentrations of
Figure 2. TDF plasma trough concentrations measured female (panel A) and male (panel B) HIV infected patients stratified
according to median body weight (**p,0.01).
doi:10.1371/journal.pone.0080242.g002
Table 2. Multivariate regression analysis of variables
independently associated with tenofovir plasma trough
concentrations.
Variable
Correlation
coefficient p-value
Gender 0.1085 0.976
Age 0.2350 0.708
Concomitant ARV drugs 20.1244 0.253
Body weight 20.2635 0.002
Serum creatinine 0.2480 0.003
AST, IU/L 0.0351 0.900
ALT, IU/L 0.0190 0.751
Hepatitis C co-infection 20.1004 0.250
ARV: antiretroviral.
doi:10.1371/journal.pone.0080242.t002
Body Weight, Female Gender and Tenofovir Exposure
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89.1%. Intrapatient variability, estimated in patients with at least 3
assessments of TDF concentrations (n = 37), was 36.0%.
Clinical factors associated with TDF plasma
concentrations
By multivariate regression analysis (Table 2), the factors
independently associated with plasma TDF concentrations were
serum creatinine (p = 0.003) and body weight (p = 0.002). This
trend was confirmed also when using creatinine clearance
(p = 0.002) and body mass index (p = 0.005) instead of serum
creatinine and body weight, respectively. In order to further
investigate the relationship between body weight and TDF plasma
concentrations we repeated the statistical analysis stratifying the
patients by gender and by weight using the median values as cutoff
(50 kg for women and 65 kg for men). Using this approach we
found that women with body weight,50 kg (n = 20) had
significantly higher plasma TDF concentrations than those
weighting $50 Kg (n = 20, 160693 vs.71652 ng/mL, p,0.001,
Figure 2, panel A). This association was not observed in men
(Figure 2, panel B).
No difference was found in the TDF plasma trough concentra-
tions when stratifying data according to concomitant antiretroviral
drugs (120.5688.6 vs. 94.3655.6 vs. 106.6671.2 ng/mL in
patients concomitantly treated with PI, NNRTI and RAL,
respectively). Similarly, no age-related differences in plasma
TDF concentrations were found in our HIV-infected adult
patients (data not shown).
TDF plasma concentrations and drug-related toxicity
Twenty-six out of the 100 HIV-positive patients enrolled in the
present study experienced either kidney (n = 11), or bone disease
(n = 11) or both complications (n = 4). The comparison of
demographic, hematochemical and clinical characteristics of
HIV-infected patients that did (n = 26) or did not (n = 74) develop
TDF-related adverse events is shown in Table 3. Patients
experiencing TDF-related toxicity had significantly higher plasma
drug concentrations (1456103 vs. 101667 ng/mL, p = 0.016),
were significantly older than those with no TDF-related toxicity
(48611 vs. 43610 years, p = 0.031) and showed a non-significant
trend for longer exposure to TDF. The independent association
between TDF plasma trough concentrations and drug-related
toxicity was confirmed also by multivariate logistic regression
analysis (p = 0.008). No significant associations between immuno-
virologic status or HCV/HBV co-infection and TDF-related
toxicity were found.
Overall, 40 HIV-infected women with median body weight of
50 kg (ranging from 36 to 83 kg) and median age of 46 years
(ranging from 26 to 68 years) were enrolled in the present study.
Thirty-two percent of women with body weight#50 kg vs. 18% of
women with body weight .50 kg experienced TDF-related
toxicity. Women experiencing toxicity had TDF plasma concen-
trations significantly higher than those who did not experience
drug related adverse events (1736131 vs. 106665 ng/mL,
p = 0.042), with no differences concerning patients ’age (4367
vs. 4468 years, p = 0.656). Such associations were not found in
men (data not shown).
Discussion and Conclusion
This is the first retrospective, observational study showing that
women, but not men, with low body weight have the highest risk
of being overexposed to TDF plasma concentrations, ultimately
increasing their risk of developing renal and/or bone complica-
tions. The following indirect clinical evidence supports this
observation. A cross-sectional survey in a French hospital-based
cohort involving 2500 HIV-infected patients showed a high
prevalence of renal impairment that was significantly associated
with female gender, age, body mass index and use of TDF [18].
The predictive role of low body mass index and female gender on
the development of renal dysfunction was also confirmed in
cohorts of HIV-infected patients from Tanzania [19] and from
Europe [20].
As additional findings, we documented that patients treated
with TDF at 300 mg/daily showed a wide distribution of TDF
Table 3. Comparison of demographic, haematological and biochemical parameters of HIV-positive patients that did (n = 26) or did
not (n = 74) develop tenofovir-related adverse events (data were given as mean 6 standard deviation).
Parameters Toxicity YES (n =26) Toxicity NO (n=74) P-value
Tenofovir therapy, days 13406927 9456909 0.068
Tenofovir conc., ng/mL 1456103 101667 0.016
Male gender, % 61.5 57.9 0.781
Age, years 48611 43610 0.031
Protease inhibitors, % 69 61 0.235*
Non nucleoside reverse transcriptase inhibitors, % 19 19
Raltegravir,% 12 20
Weight, Kg 63615 62614 0.815
Body mass index, Kg/m2 22.564.8 21.463.4 0.206
AST, IU/L 48645 58685 0.555
ALT, IU/L 53677 716149 0.573
CD4, cells/mL 5536292 4536257 0.102
HIV-RNA, cp/mL 13140664067 30161334 0.087
Pts with HIV-RNA .100 cp/mL, % 12 18 0.265*
Hepatitis C co-infection, % 46 45 0.907
*chi square test.
doi:10.1371/journal.pone.0080242.t003
Body Weight, Female Gender and Tenofovir Exposure
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plasma trough concentrations, and confirmed that renal function
and body weight were the two major sources for the observed
interindividual variability of TDF pharmacokinetics, as previously
reported [21–23]. These observations underline the importance of
close monitoring for renal and bone function in patients with low
body weight treated with conventional TDF dose regimens
[13,14].
More recently, a retrospective analysis from the Swiss HIV
Cohort study has shown that TDF with either boosted protease
inhibitors (lopinavir or atazanavir) lead to a greater initial decline
in estimated GFR than TDF with efavirenz [24]. This result has
been related to a drug-to-drug interaction with protease inhibitors
resulting in a 30% increase in plasma levels of TDF and a
consequent greater increase in the renal damage [25]. In our study
we found no significant differences in the TDF plasma trough
concentrations between patients taking protease inhibitors, efavir-
enz/nevirapine or raltegravir. The lack of significant association
between TDF plasma levels and concomitant HAART medica-
tions was also confirmed by multivariate regression analysis.
Similarly, concomitant use of protease inhibitors vs. NNRTI was
not independently associated with the development of TDF-
related adverse events. The discrepancy between our and previous
results can be only apparent and due, at least in part, to the
different periods of observation in the two studies. In the study by
Young and co-workers [24] the differences between protease
inhibitors and NNRTI on GFR decline, significant in the first 6
months of therapy, did attenuate thereafter; this is in line with our
study that involved patients being at more than 6 months of
therapy with TDF.
In the cohort we studied, we found that patients experiencing
TDF-related adverse events were significantly older, with signif-
icantly higher TDF plasma trough concentration, and with longer
exposure to TDF than patients that did not experience drug
toxicity. Our data are in agreement with previous findings in a
large cohort of adults HIV-infected subjects [15], showing that
patients with kidney tubular dysfunction had significantly higher
TDF plasma trough concentrations than those with normal renal
function. Taken together, these results suggest an association
between high TDF plasma concentrations and the development of
long-term TDF-related complications (irreversible renal insuffi-
ciency and/or bone mineral loss). Given the retrospective nature
of our investigation, we are not able to conclude whether it is
chronic overexposure to TDF that determined reduced glomerular
filtration rate or, conversely, that the progressive development of
renal insufficiency resulted in an accumulation of TDF that is
excreted through glomerular filtration. Moreover, given the
limited number of HIV-infected women included in the statistical
analyses, we were not able to provide definitive conclusions but,
rather, a working hypothesis to be further investigated in
prospective, adequately powered clinical trials. We believe,
however, that these results also show that therapeutic monitoring
of TDF plasma trough concentrations, taken as surrogate marker
of systemic drug exposure, may allow the early identification of
patients at risk of toxicity related to overexposure to TDF. In these
patients modified dosing regimens (i.e. dose-interval adjustments)
could be eventually pursued with the goal to reduce adverse events
related to high levels of TDF exposure.
In summary, High TDF plasma trough concentrations and
patients’ age were independently associated with the development
of drug-related kidney and bone toxicity. HIV-infected women
with low body weight are at risk to be exposed to high TDF
plasma trough concentrations, ultimately resulting in a significant
hazard to develop drug-related complications. This could be
eventually handled by routine therapeutic monitoring of TDF
plasma concentrations.
Results of our study also confirmed the emerging evidence that
HIV-infected female subjects are more susceptible to adverse
events related to antiretroviral treatment [25,26]. In order to
optimize treatment in all HIV-infected patients, there is the
compelling need for specific studies and female participation in
both cohort studies and clinical trials should be promoted.
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